×
About 224,384 results
BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing - Draft Recommendation Statement
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Feb 19th, 2019 - The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer or have an ethnicity or ancestry associated with BRCA1 or BRCA2 gene mutations with one of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibi...

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015
https://jamanetwork.com/journals/jama/fullarticle/2724897?resultClick=1
Mahal, B. et. al.

Feb 10th, 2019 - Historically, most patients with low-risk prostate cancer (clinical category T1c-T2a, prostate-specific antigen level <10 ng/mL, and Gleason 6 disease) were treated with radical prostatectomy, while radiotherapy-based treatment was the favored approach for high-risk localized prostate cancer. However, conservative management of low-risk prostate cancer with active surveillance or watchful waiti...

ASCO 2019 Report — Lung Cancer
https://www.jwatch.org/na49290/2019/06/18/asco-2019-report-lung-cancer

Jun 17th, 2019 - At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Associate Editor, Anne S. Tsao, MD, reviews key presentations on new treatments for patients with non...

FDA approves new treatment for pediatric patients with type 2 diabetes
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes

Jun 16th, 2019 - The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
https://jnccn.org/view/journals/jnccn/17/6/article-p650.xml
Journal of the National Comprehensive Cancer Network;

Jun 15th, 2019 - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/ref...

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/6/article-p721.xml
Journal of the National Comprehensive Cancer Network;

Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guid...

Building Systems to Address Tobacco Use in Oncology: Early Benefits and Opportunities From the Cancer Center Cessation Initiative
https://jnccn.org/view/journals/jnccn/17/6/article-p638.xml
Journal of the National Comprehensive Cancer Network; Jenssen, B. et. al.

Jun 14th, 2019 - The 2014 Surgeon General’s report underscored the importance of helping patients with cancer quit smoking, because continued smoking after a diagnosis is causally linked to cancer-specific and all-cause mortality.1 More than 50% of patients with cancer who smoked before diagnosis continue to smoke after diagnosis and treatment,2 leading to calls from NCCN,3 ASCO,4 and the American Association f...

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
https://www.amgen.com/media/news-releases/2019/06/fda-approves-amgen-and-allergans-kanjinti-trastuzumabanns-a-biosimilar-to-herceptin-trastuzumab/

Jun 12th, 2019 - Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarc...

Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis
https://doi.org/10.7326/M19-0223
Annals of Internal Medicine; Cohen, J. et. al.

Jun 10th, 2019 - Background: The long-term cardiovascular risk of isolated elevated office blood pressure (BP) is unclear. Purpose: To summarize the risk for cardiovascular events and all-cause mortality associated with untreated white coat hypertension (WCH) and treated white coat effect (WCE). Data Sources: PubMed and EMBASE, without language restriction, from inception to December 2018. Study Sel...

FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-two-new-indications-mercks-keytruda-pembrolizum

Jun 10th, 2019 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU), a commonly used chemotherapy regimen, for the first-line treatment o...

Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2735345
JAMA US Preventive Services Task Force

Jun 10th, 2019 - Importance Approximately 1.1 million persons in the United States are currently living with HIV, and more than 700 000 persons have died of AIDS since the first cases were reported in 1981. There were approximately 38 300 new diagnoses of HIV infection in 2017. The estimated prevalence of HIV infection among persons 13 years and older in the United States is 0.4%, and data from the Centers for...

Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2735508
JAMA US Preventive Services Task Force

Jun 10th, 2019 - Importance Effective prevention strategies for HIV infection are an important public health priority. Preexposure prophylaxis (PrEP) involves use of antiretroviral therapy (ART) daily or before and after sex to decrease risk of acquiring HIV infection. Objective To synthesize the evidence on the benefits and harms of PrEP, instruments for predicting incident HIV infection, and PrEP adheren...

Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2735343
JAMA US Preventive Services Task Force

Jun 10th, 2019 - Importance Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3. Objective To update the 2012 review on HIV screening to infor...

Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2735344
JAMA US Preventive Services Task Force

Jun 10th, 2019 - Objective To update the 2012 review on prenatal HIV screening to inform the USPSTF. Data Sources Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019. Study Selection Pregnant persons 13 years and older; randomized clinical trials and cohort studies of screening v...

Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2735509
JAMA US Preventive Services Task Force

Jun 10th, 2019 - Importance An estimated 1.1 million individuals in the United States are currently living with HIV, and more than 700 000 persons have died of AIDS since the first cases were reported in 1981. In 2017, there were 38 281 new diagnoses of HIV infection reported in the United States; 81% of these new diagnoses were among males and 19% were among females. Although treatable, HIV infection has no c...

Binge Drinking and Prescription Opioid Misuse in the U.S., 2012–2014
https://www.ajpmonline.org/article/S0749-3797(19)30157-6/fulltext
American Journal of Preventive Medicine; Esser, M et. al.

Jun 10th, 2019 - Introduction Prescription opioids were responsible for approximately 17,000 deaths in the U.S. in 2016. One in five prescription opioid deaths also involve alcohol. Drinkers who misuse prescription opioids (i.e., use without a prescription or use only for the experience or feeling it causes) are at a heightened risk of overdose. However, little is known about the relationship between drinking ...

3 simple steps could save 94 million lives
https://www.heart.org/en/news/2019/06/10/3-simple-steps-could-save-94-million-lives

Jun 9th, 2019 - Doing three relatively easy things could help save 94.3 million people around the world from premature deaths caused by cardiovascular disease, new research suggests. Those lives could be saved over a quarter-century span by scaling up treatment of high blood pressure, reducing sodium intake and eliminating artificial trans fat, according to a study published Monday in the American Heart Ass...

FDA permits marketing of first medical device for relief of pain associated with irritable bowel syndrome in patients 11-18 years of age
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-relief-pain-associated-irritable-bowel-syndrome-patients

Jun 6th, 2019 - The U.S. Food and Drug Administration today permitted marketing of the first medical device to aid in the reduction of functional abdominal pain in patients 11-18 years of age with irritable bowel syndrome (IBS) when combined with other therapies for IBS. IBS is a condition affecting the large intestines that can cause abdominal pain and discomfort typically related to bowel movements. “This...

Vitamin D Supplementation and Prevention of Type 2 Diabetes
https://www.nejm.org/doi/10.1056/NEJMoa1900906
New England Journal of Medicine; Pittas. A., et al

Jun 6th, 2019 - Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the risk of diabetes is unknown. METHODS We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hou...

FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks

Jun 3rd, 2019 - The U.S. Food and Drug Administration today approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, M.D., deputy director of ...